Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference Read more about Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Aimmune Therapeutics Reports Second Quarter 2015 Financial Results Read more about Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Read more about Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aimmune Therapeutics Announces Pricing of Initial Public Offering Read more about Aimmune Therapeutics Announces Pricing of Initial Public Offering
Allergen Research Corporation Announces $17 Million Series A Financing Read more about Allergen Research Corporation Announces $17 Million Series A Financing
Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101 Read more about Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101
Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Announces Positive Phase 2 Study Results of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment Read more about Aimmune Therapeutics to Announce Phase 2 Data at EAACI Congress 2015 for Study of Peanut Allergy Desensitization Treatment
Allergen Research Corporation Renamed Aimmune Therapeutics Read more about Allergen Research Corporation Renamed Aimmune Therapeutics
